QCM
SRPT icon

Quantinno Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Quantinno Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
68,453
-22,755
-25% -$430K ﹤0.01% 2405
2026
Q1 		$1.98M Sell
91,208
-16,377
-15% -$317K ﹤0.01% 1625
2025
Q4 		$2.32M Buy
107,585
+46,915
+77% +$989K ﹤0.01% 1311
2025
Q3 		$1.17M Buy
60,670
+43,339
+250% +$773K ﹤0.01% 1412
2025
Q2 		$296K Buy
+17,331
New +$739K ﹤0.01% 2030

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Quantinno Capital Management's SRPT Position: Q2 2026 in Review

Quantinno Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 25% in Q2 2026, selling an estimated $430K and leaving 68,453 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2405.

Quantinno Capital Management first reported a position in SRPT in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.32M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Quantinno Capital Management held 68,453 shares of Sarepta Therapeutics worth $1.23M as of Q2 2026.
  • Quantinno Capital Management sold 22,755 Sarepta Therapeutics shares in Q2 2026, an estimated $430K.
  • Sarepta Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2405 holding.
  • Quantinno Capital Management first reported a position in Sarepta Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Quantinno Capital Management's Sarepta Therapeutics position peaked at $2.32M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.